Two types of treatment targeting different genetic mutations show promising results in clinical studies.

Risk reduction was most impressive among men, but greater vaccine coverage is needed for maximum impact.

Lynparza (olaparib) was nearly twice as likely as chemotherapy to shrink tumors in women with metastatic breast cancer.

More treatment options may soon become available for those with hepatocellular carcinoma (HCC), which is often diagnosed late.

Two trials show that adding Zytiga to standard treatment for advanced prostate cancer reduces death risk.

Keytruda shows promise in treating an aggressive form of the cancer that occurs more often in younger women, especially young Black women.

Findings from three clinical trials of larotrectinib were presented at this year’s American Society of Clinical Oncology in Chicago.